Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
Profound Medical (NASDAQ:PROF; TSX:PRN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Rhea-AI Summary
Profound Medical (NASDAQ:PROF; TSX:PRN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and discuss business developments.
Investors can register for the live call via the provided online registration link, and the conference will also be broadcast live and subsequently archived in the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PROF
In the Jul 17 session, PROF gained 1.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Results date
- August 6, 2026
- Scheduled release of second quarter 2026 financial results
- Conference call time
- 4:30 p.m. ET
- Start time for Q2 2026 results call
- Quarter
- Second quarter 2026
- Upcoming financial reporting period
Previous Conferences,earnings date Reports
-
Scheduled reporting of Q1 2026 results and post-close conference call.
-
Set date for Q4 and full-year 2025 results with investor call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Second Quarter 2026 Results Conference Call Details:
Date: Thursday, August 6, 2026
Time: 4:30 p.m. ET
Live Call Registration: https://register-conf.media-server.com/register/BI1680e67d2b6f4f81b268df3183400d7c
The call will also be broadcast live and archived on the Company's website in the Investors section here.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care — from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.